Advertisement
Advertisement
U.S. markets open in 3 hours 54 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Mainz Biomed B.V. (4TO.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
6.00+0.13 (+2.28%)
As of 08:02AM CET. Market open.
Advertisement

Mainz Biomed B.V.

Robert Koch Strasse 50
Mainz 55129
Germany
49 6131 554 2860
https://mainzbiomed.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Guido BaechlerCEO & DirectorN/AN/A1965
Mr. William J. CaragolChief Financial OfficerN/AN/A1967
Mr. Philipp FreeseChief Operating OfficerN/AN/A1983
Dr. Moritz Eidens Ph.D.Chief Science Officer & DirectorN/AN/A1984
Stefan ErlachHead of HRN/AN/AN/A
Mr. Darin S. LeighChief Commercial OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Corporate Governance

Mainz Biomed B.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement